{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:11:32Z","timestamp":1770743492349,"version":"3.49.0"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T00:00:00Z","timestamp":1339977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To examine the safety and tolerability of rapidly initiating adjunctive lacosamide via a single intravenous loading dose followed by twice\u2010daily oral lacosamide in lacosamide\u2010naive adults with partial\u2010onset seizures.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> This open\u2010label, multicenter trial, enrolled patients with epilepsy who were taking 1\u20132 antiepileptic drugs (AEDs) in one of four sequential cohorts containing 25 subjects each. An intravenous lacosamide loading dose (200, 300, or 400\u2003mg) was administered over 15 min followed 12\u2003h later by initiation of oral dosing consisting of one\u2010half of the loading dose administered twice daily for 6.5\u2003days. The first cohort was administered lacosamide 200\u2003mg\/day, followed by a cohort at 300\u2003mg\/day, and then a cohort at 400\u2003mg\/day. The results from each cohort were evaluated before enrolling the next highest dose level. The fourth cohort enrolled patients at the highest dose with clinically acceptable safety and tolerability results. Safety evaluations included treatment\u2010emergent adverse events (TEAEs), patient withdrawals due to TEAEs, and changes in vital signs, 12\u2010lead electrocardiography (ECG) studies, laboratory parameters, and clinical examinations. Postinfusion lacosamide plasma concentrations were also evaluated.<\/jats:p><jats:p><jats:bold>Key Findings:\u2002<\/jats:bold> A total of 100 patients were enrolled, 25 in each cohort. The loading dose for the repeat cohort was 300\u2003mg; therefore, 25 patients were enrolled at 200\u2003mg\/day, 50 at 300\u2003mg\/day, and 25 at 400\u2003mg\/day. Most TEAEs occurred within the first 4\u2003h following infusion; dose\u2010related TEAEs (incidence \u226510%) during this timeframe included dizziness, somnolence, and nausea. Seven patients withdrew, all due to TEAEs: three (6%) from the combined 300\u2003mg group and four (16%) from the 400\u2003mg group; four of these patients discontinued within 4\u2003h following infusion. The most common TEAEs leading to discontinuation (overall incidence &gt;1%) were dizziness (6%), nausea (5%), and vomiting (3%). No clinically relevant pattern of changes from baseline ECG, clinical laboratory parameters, or vital signs were observed. Trough plasma concentrations suggested that near steady\u2010state lacosamide concentrations were achieved with a single intravenous loading dose.<\/jats:p><jats:p><jats:bold>Significance:\u2002<\/jats:bold> Intravenous loading doses of 200 and 300\u2003mg lacosamide administered over 15\u2003min followed by oral lacosamide were well tolerated in lacosamide\u2010naive patients. The 400\u2010mg loading dose was less well tolerated due to a higher frequency of dose\u2010related TEAEs. These results support the feasibility of rapid initiation of adjunctive lacosamide treatment.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2012.03543.x","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T20:14:48Z","timestamp":1340050488000},"page":"58-65","source":"Crossref","is-referenced-by-count":44,"title":["Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide\u2010naive patients with partial\u2010onset seizures"],"prefix":"10.1111","volume":"54","author":[{"given":"Nathan B.","family":"Fountain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouko","family":"Isojarvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanne","family":"Dilley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Doty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. David","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01188.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.09.005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01317.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02496.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01951.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01423.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02463.x"},{"key":"e_1_2_7_9_1","first-page":"123","article-title":"Bioequivalence of short\u2010time infusions compared to oral administration of lacosamide","volume":"45","author":"Kropeit D","year":"2004","journal-title":"Epilepsia"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584860-000000000-00000"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.1.49"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2012.03543.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2012.03543.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:16:50Z","timestamp":1698664610000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2012.03543.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,18]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1528-1167.2012.03543.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03543.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,18]]}}}